BIOTRICITY INC (BTCY) Stock Price, Quote, News and Overview
NASDAQ:BTCY - Nasdaq - US09074H2031 - Common Stock - Currency: USD
BTCY Quote, Performance and Key Statistics
0.4631
-0.18 (-28.31%)
The current stock price of BTCY is 0.4631 USD. In the past month the price decreased by -39.51%. In the past year, price decreased by -81.7%.
BTCY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 36.13 | 36.66B | ||
| DOCS | DOXIMITY INC-CLASS A | 56.54 | 13.58B | ||
| WAY | WAYSTAR HOLDING CORP | N/A | 7.26B | ||
| CERT | CERTARA INC | 33.77 | 2.12B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.98B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 15.03 | 1.83B | ||
| SDGR | SCHRODINGER INC | N/A | 1.65B | ||
| PHR | PHREESIA INC | N/A | 1.64B | ||
| EVH | EVOLENT HEALTH INC - A | 15.8 | 1.22B | ||
| HSTM | HEALTHSTREAM INC | 50.58 | 999.88M | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 966.46M | ||
| DH | DEFINITIVE HEALTHCARE CORP | 14.47 | 762.50M |
Related stock screener links
About BTCY
Company Profile
Biotricity, Inc. is a medical technology company, which engages in biometric data monitoring solutions. The company is headquartered in Redwood City, California and currently employs 55 full-time employees. The company went IPO on 2015-10-26. The firm developed its Bioflux technology, comprised of a monitoring device and software components. The Bioflux device is comprised of a wet electrode worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patient’s electrocardiogram (ECG) data for monitoring and diagnostic purposes. Its Bioflux platform has a built-in cellular chipset and a real-time embedded operating system, which allows for its technology to be utilized as an Internet of Things (IoT) platform. The company has developed several technologies, including Biotres, Bioheart, and Biocare. Biotres is an ECG Holter solution that addresses the limitations of existing solutions in the Holter market. Bioheart is a personal cardiac monitoring solution for consumers. Biocare is a cardiac disease management platform for chronic care management and remote patient monitoring.
Company Info
BIOTRICITY INC
203 Redwood Parkway, Suite 600
Redwood City CALIFORNIA US
Employees: 55
Company Website: https://www.biotricity.com/
Phone: 16508321626
BIOTRICITY INC / BTCY FAQ
What is the stock price of BIOTRICITY INC today?
The current stock price of BTCY is 0.4631 USD. The price decreased by -28.31% in the last trading session.
What is the ticker symbol for BIOTRICITY INC stock?
The exchange symbol of BIOTRICITY INC is BTCY and it is listed on the Nasdaq exchange.
On which exchange is BTCY stock listed?
BTCY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOTRICITY INC stock?
6 analysts have analysed BTCY and the average price target is 4.08 USD. This implies a price increase of 781.02% is expected in the next year compared to the current price of 0.4631. Check the BIOTRICITY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOTRICITY INC worth?
BIOTRICITY INC (BTCY) has a market capitalization of 9.95M USD. This makes BTCY a Nano Cap stock.
How many employees does BIOTRICITY INC have?
BIOTRICITY INC (BTCY) currently has 55 employees.
What are the support and resistance levels for BIOTRICITY INC (BTCY) stock?
BIOTRICITY INC (BTCY) has a resistance level at 1.1. Check the full technical report for a detailed analysis of BTCY support and resistance levels.
Is BIOTRICITY INC (BTCY) expected to grow?
The Revenue of BIOTRICITY INC (BTCY) is expected to grow by 19.17% in the next year. Check the estimates tab for more information on the BTCY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOTRICITY INC (BTCY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BTCY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BTCY, evaluating the profitability, health, valuation and growth aspects
- BIOTRICITY INC (BTCY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOTRICITY INC (BTCY) Sales and EPS estimates to see what analysts future expectations are.
- BIOTRICITY INC (BTCY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOTRICITY INC (BTCY) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOTRICITY INC (BTCY) Stock Chart to make your own analysis
- BIOTRICITY INC (BTCY) Latest news and press-releases to stay up to date.
Does BIOTRICITY INC (BTCY) stock pay dividends?
BTCY does not pay a dividend.
When does BIOTRICITY INC (BTCY) report earnings?
BIOTRICITY INC (BTCY) will report earnings on 2024-08-12, after the market close.
What is the Price/Earnings (PE) ratio of BIOTRICITY INC (BTCY)?
BIOTRICITY INC (BTCY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.66).
What is the Short Interest ratio of BIOTRICITY INC (BTCY) stock?
The outstanding short interest for BIOTRICITY INC (BTCY) is 1.04% of its float. Check the ownership tab for more information on the BTCY short interest.
BTCY Technical Analysis
BTCY Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BTCY. BTCY may be in some trouble as it scores bad on both profitability and health.
BTCY Financial Highlights
Over the last trailing twelve months BTCY reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS increased by 26.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -251.17% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BTCY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to BTCY. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 73.56% and a revenue growth 19.17% for BTCY